<DOC>
	<DOCNO>NCT00635817</DOCNO>
	<brief_summary>The purpose study determine 11.25 30 mg formulation leuprolide effective treating child Central Precocious Puberty ( CPP ) .</brief_summary>
	<brief_title>A Study Leuprolide 11.25 mg 30 mg Administered Every 3 Months Treat Central Precocious Puberty</brief_title>
	<detailed_description>Study Design : A total 80 child confirm CPP plan enrol randomized 1:1 ratio receive 2 injection either leuprolide acetate 11.25 mg 30 mg depot formulation , injection administer 3 mo apart ( 6 mo treatment ) : This study include 4-week Screening Period , two 3-mo treatment cycle , posttreatment follow-up period ( 12 week follow Mo 6 visit ) . Study visit occur Screening , Day 1 , Week 2 ( subject participate pharmacokinetic subset ) , Mo 1 , 2 , 3 , Mo 6/Early Termination , 12 week later , Posttreatment Follow-up Visit . This study conduct 18 site United States 4 site Puerto Rico .</detailed_description>
	<mesh_term>Puberty , Precocious</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Subject clinical diagnosis CPP . Eligible receive least 6 mo therapy treat CPP study entry . Bone age advance least 1 year beyond chronological age time diagnosis first treatment . In general good health uncontrolled , clinically significant disease would interfere bone maturation mask objective protocol assess investigator . Additional criterion subject previous treatment : Girls 28 year inclusive Boys 29 year inclusive Day 1 . Has pretreatment pubertal response leuprolide acetate stimulation ( luteinizing hormone â‰¥8 mIU/mL ) Screening . Breast pubertal stag least 2 girl ; testicular volume least 4 cc testicular length great 2.5 cm boy Screening . Additional criterion subject previously treat : Girls 210 year inclusive boys 211 year inclusive Day 1 . Must standard gonadotropin release hormone analog therapy least 6 mo prior Day 1 . Has document maintenance luteinizing hormone suppression evidence peak stimulated level &lt; 4 mIU/mL Screening . Incomplete precocious puberty ( premature thelarche , premature adrenarche ) . Peripheral precocious puberty : gonadal adrenal tumor , congenital adrenal hyperplasia , testotoxicosis boy , human chorionic gonadotropin secrete tumor McCuneAlbright syndrome girl . Evidence abnormal pituitary , hypothalamic , adrenal , thyroid gonadal function premature secretion gonadotropin adequately control . Unstable intracranial tumor ( unresponsive treatment/expanding ) except hamartoma . Previous treatment GnRHa therapy require leuprolide acetate depot suspension &gt; 15 mg monthly . Bone age &gt; 13 year girls &gt; 14 year boys . Any condition interfering growth , ie , skeletal dysplasia , cerebral palsy . Chronic illness require treatment may interfere growth , ie , chronic steroid use , renal failure , moderate severe scoliosis . Diagnosis short stature , ie 2.25 standard deviation mean height age ( growth chart measurement ) . Prior current therapy medroxyprogesterone acetate growth hormone . Has abnormal laboratory value suggest clinically significant underlying disease . Creatinine &gt; 1.5 mg/dL , alanine aminotransferase and/or aspartate aminotransferase &gt; 2.0 x upper limit normal , total bilirubin &gt; 2.0 mg/dL aspartate aminotransferase/alanine aminotransferase elevate normal limit . Positive pregnancy test . Known hypersensitivity study medication excipients . Participation another drug research within 3 mo enrollment study . Prior current therapy insulinlike growth factor1 . Use estrogen preparation within 2 mo prior Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>CPP</keyword>
	<keyword>central precocious puberty</keyword>
	<keyword>pediatrics</keyword>
	<keyword>suppression luteinizing hormone</keyword>
	<keyword>Lupron</keyword>
	<keyword>leuprolide acetate</keyword>
	<keyword>depot formulation</keyword>
	<keyword>GnRHa</keyword>
	<keyword>GnRH agonist</keyword>
	<keyword>GnRH analog</keyword>
	<keyword>luteinizing hormone</keyword>
</DOC>